WO2018013559A1 - Nouveaux composés et leurs utilisations - Google Patents
Nouveaux composés et leurs utilisations Download PDFInfo
- Publication number
- WO2018013559A1 WO2018013559A1 PCT/US2017/041526 US2017041526W WO2018013559A1 WO 2018013559 A1 WO2018013559 A1 WO 2018013559A1 US 2017041526 W US2017041526 W US 2017041526W WO 2018013559 A1 WO2018013559 A1 WO 2018013559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- alkyl
- compound
- hydroxy
- carbon atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 355
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 229940011871 estrogen Drugs 0.000 claims abstract description 11
- 239000000262 estrogen Substances 0.000 claims abstract description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 183
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 95
- 125000001072 heteroaryl group Chemical group 0.000 claims description 73
- 125000000623 heterocyclic group Chemical group 0.000 claims description 73
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 229910052799 carbon Inorganic materials 0.000 claims description 70
- 229910052760 oxygen Inorganic materials 0.000 claims description 68
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims description 63
- 102100038595 Estrogen receptor Human genes 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 125000002252 acyl group Chemical group 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 36
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 33
- 230000001225 therapeutic effect Effects 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 24
- 206010006187 Breast cancer Diseases 0.000 claims description 20
- 208000026310 Breast neoplasm Diseases 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 229960001603 tamoxifen Drugs 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 206010014733 Endometrial cancer Diseases 0.000 claims description 11
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 11
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 201000004101 esophageal cancer Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000003981 vehicle Substances 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 150000003852 triazoles Chemical class 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical group CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 claims description 4
- 208000004483 Dyspareunia Diseases 0.000 claims description 4
- 208000021197 IgG4-related mesenteritis Diseases 0.000 claims description 4
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 4
- 208000004052 Peritoneal Panniculitis Diseases 0.000 claims description 4
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 201000000079 gynecomastia Diseases 0.000 claims description 4
- 208000000509 infertility Diseases 0.000 claims description 4
- 230000036512 infertility Effects 0.000 claims description 4
- 231100000535 infertility Toxicity 0.000 claims description 4
- 230000009245 menopause Effects 0.000 claims description 4
- 230000000624 ovulatory effect Effects 0.000 claims description 4
- 206010034674 peritonitis Diseases 0.000 claims description 4
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 4
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical group CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 10
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 3
- -1 butadienyl Chemical group 0.000 description 94
- 239000000203 mixture Substances 0.000 description 77
- 210000004027 cell Anatomy 0.000 description 61
- 150000001721 carbon Chemical group 0.000 description 51
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 46
- 239000007787 solid Substances 0.000 description 43
- DFNAHNDQNLTHEO-IZHYLOQSSA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCOC(NC)=O)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCOC(NC)=O)C=C1 DFNAHNDQNLTHEO-IZHYLOQSSA-N 0.000 description 38
- 125000005843 halogen group Chemical group 0.000 description 37
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 230000015556 catabolic process Effects 0.000 description 21
- 238000006731 degradation reaction Methods 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 229940125904 compound 1 Drugs 0.000 description 18
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 15
- 229940124597 therapeutic agent Drugs 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 239000003886 aromatase inhibitor Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 229960005322 streptomycin Drugs 0.000 description 10
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 9
- 229940122815 Aromatase inhibitor Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 8
- 229930182555 Penicillin Natural products 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960002258 fulvestrant Drugs 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol group Chemical group [C@@H]12CC[C@H](O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000003080 antimitotic agent Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000003413 degradative effect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Chemical group 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 5
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical group [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical group SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001378 electrochemiluminescence detection Methods 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 150000002576 ketones Chemical group 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical group 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- NFVUAUVSFDFOJT-UHFFFAOYSA-N octanediamide Chemical compound NC(=O)CCCCCCC(N)=O NFVUAUVSFDFOJT-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZLOXMSNKPDWMEF-ZIFCJYIRSA-N (2s,4r)-1-[(2s)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-n-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound N1=CSC(C=2C=CC(CNC(=O)[C@H]3N(C[C@H](O)C3)C(=O)[C@@H](N)C(C)(C)C)=CC=2)=C1C ZLOXMSNKPDWMEF-ZIFCJYIRSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VJGJRYDPBSPWAZ-MEIHLTSWSA-N 2-[2-[2-[2-[2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-methylamino]-2-oxoethoxy]ethoxy]ethoxy]acetic acid Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(COCCOCCOCC(=O)O)=O)C)C=C1 VJGJRYDPBSPWAZ-MEIHLTSWSA-N 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZQMDIRYABSKDIE-AATIZZAJSA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 ZQMDIRYABSKDIE-AATIZZAJSA-N 0.000 description 2
- 0 CCC(c1ccc(*)cc1)=C(c1ccc(*)cc1)c1ccc(*CCN(*)C(IC(N(*)[C@@](*)C(N(C[C@@](C2)O)[C@@]2C(NCc2ccc(*)cc2)=O)=O)=O)=O)cc1 Chemical compound CCC(c1ccc(*)cc1)=C(c1ccc(*)cc1)c1ccc(*CCN(*)C(IC(N(*)[C@@](*)C(N(C[C@@](C2)O)[C@@]2C(NCc2ccc(*)cc2)=O)=O)=O)=O)cc1 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- JTQWWGKQJVDNKE-UIMQSWDRSA-N N'-[2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl]-N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[(4-quinazolin-6-ylphenyl)methylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]-N'-methylundecanediamide Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C=2C=C3C=NC=NC3=CC=2)=O)C(C)(C)C)=O)C)C=C1 JTQWWGKQJVDNKE-UIMQSWDRSA-N 0.000 description 2
- NYDCDZSEEAUOHN-IZHYLOQSSA-N N-Desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=CC=C1 NYDCDZSEEAUOHN-IZHYLOQSSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 101000776133 Viola hederacea Leaf cyclotide 1 Proteins 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940044684 anti-microtubule agent Drugs 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- OJEPEHNTDPXZSY-UHFFFAOYSA-N cyclobutane-1,3-dicarboxamide Chemical compound NC(=O)C1CC(C(N)=O)C1 OJEPEHNTDPXZSY-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- 229960004421 formestane Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- HJZZQNLKBWJYPD-UHFFFAOYSA-N 2-[2-[2-(carboxymethoxy)ethoxy]ethoxy]acetic acid Chemical compound OC(=O)COCCOCCOCC(O)=O HJZZQNLKBWJYPD-UHFFFAOYSA-N 0.000 description 1
- QIMQCARYIBIRDS-GYHWCHFESA-N 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]acetic acid Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC(O)=O)=CC=1)/C1=CC=CC=C1 QIMQCARYIBIRDS-GYHWCHFESA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- DDCOGIMXXHFKGC-UHFFFAOYSA-N 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazoline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N=CN=C2)C2=C1 DDCOGIMXXHFKGC-UHFFFAOYSA-N 0.000 description 1
- KOVPXZDUVJGGFU-UHFFFAOYSA-N 8-methoxy-8-oxooctanoic acid Chemical compound COC(=O)CCCCCCC(O)=O KOVPXZDUVJGGFU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- IORHYXGBNBHYKN-AATIZZAJSA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CC#CCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CC#CCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 IORHYXGBNBHYKN-AATIZZAJSA-N 0.000 description 1
- QNOHFPPYZXVGOI-AATIZZAJSA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCC#CCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCC#CCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 QNOHFPPYZXVGOI-AATIZZAJSA-N 0.000 description 1
- NAUYXTUTMAEZRQ-AATIZZAJSA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCC#CCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCC#CCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 NAUYXTUTMAEZRQ-AATIZZAJSA-N 0.000 description 1
- KONJNZCUNWADTH-XFEFFQPCSA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 KONJNZCUNWADTH-XFEFFQPCSA-N 0.000 description 1
- FWAHATSZIBZTCW-UGMORNCRSA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)C)=O)C)C=C1 FWAHATSZIBZTCW-UGMORNCRSA-N 0.000 description 1
- UTUUGSRALOXCTI-BXMUYAEESA-N C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCNC(=O)C2=CC=C(C=C2)CC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(=O)NCC2=CC=C(C=C2)C2=C(N=CS2)C)C(C)(C)C)C=C1 Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCNC(=O)C2=CC=C(C=C2)CC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(=O)NCC2=CC=C(C=C2)C2=C(N=CS2)C)C(C)(C)C)C=C1 UTUUGSRALOXCTI-BXMUYAEESA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- VRZSLLPULCLNNV-SFHVURJKSA-N CC(C)(C)CC(N(C1)[C@H](CC(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)CC1=O)=O Chemical compound CC(C)(C)CC(N(C1)[C@H](CC(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)CC1=O)=O VRZSLLPULCLNNV-SFHVURJKSA-N 0.000 description 1
- GQIZNNDCIOPQOB-PKOBYXMFSA-O CC(C)(C)[C@@H](C(N(CCC1)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC([I+]C(O)=O)=O Chemical compound CC(C)(C)[C@@H](C(N(CCC1)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC([I+]C(O)=O)=O GQIZNNDCIOPQOB-PKOBYXMFSA-O 0.000 description 1
- BXVIVIZCVBNJIU-BBMPLOMVSA-N CC(C)(CC(N(CC(C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)C/[O]=C(/CCCCCCCC(O)=O)\N Chemical compound CC(C)(CC(N(CC(C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)C/[O]=C(/CCCCCCCC(O)=O)\N BXVIVIZCVBNJIU-BBMPLOMVSA-N 0.000 description 1
- GYQHVRYEOUMRMV-BDEUDEIXSA-N CC/C(/c1ccccc1)=C(/c(cc1)ccc1O)\C(C=C1)=CCC1OCCNC(CCCCCC/C(/N)=[O]/[O]=C(\CC(C)(C)C)/N(C[C@@H](C1)O)[C@@H]1C(NCc1ccc(C2SC=NC2(C)C)cc1)=O)=O Chemical compound CC/C(/c1ccccc1)=C(/c(cc1)ccc1O)\C(C=C1)=CCC1OCCNC(CCCCCC/C(/N)=[O]/[O]=C(\CC(C)(C)C)/N(C[C@@H](C1)O)[C@@H]1C(NCc1ccc(C2SC=NC2(C)C)cc1)=O)=O GYQHVRYEOUMRMV-BDEUDEIXSA-N 0.000 description 1
- MCTXGHSAMQKHRK-FOIWHSKNSA-N CC/C(/c1ccccc1)=C(\c(cc1)ccc1O)/c(cc1)ccc1OCCNC(CCCCCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C1)O)[C@@H]1C(NCC(C=C1)=CCC1c1c(C)nc[s]1)=O)=O)=O)=O Chemical compound CC/C(/c1ccccc1)=C(\c(cc1)ccc1O)/c(cc1)ccc1OCCNC(CCCCCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C1)O)[C@@H]1C(NCC(C=C1)=CCC1c1c(C)nc[s]1)=O)=O)=O)=O MCTXGHSAMQKHRK-FOIWHSKNSA-N 0.000 description 1
- AOYRMQLJMCJVSF-VCDCOPGHSA-N CC/C(/c1ccccc1)=C(\c1ccccc1)/c(cc1)ccc1OCCN(C)C(CCCCCCC/C(/N)=[O]/CC(C)(C)CC(N(CC(C1)O)[C@@H]1[IH](NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)=O Chemical compound CC/C(/c1ccccc1)=C(\c1ccccc1)/c(cc1)ccc1OCCN(C)C(CCCCCCC/C(/N)=[O]/CC(C)(C)CC(N(CC(C1)O)[C@@H]1[IH](NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)=O AOYRMQLJMCJVSF-VCDCOPGHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LLTZYHSRTJXIQO-PXRHQIMWSA-N N'-[2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl]-N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]-N'-methyloctanediamide Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCC(=O)N[C@H](C(=O)N2[C@@H](C[C@H](C2)O)C(NCC2=CC=C(C=C2)C2=C(N=CS2)C)=O)C(C)(C)C)=O)C)C=C1 LLTZYHSRTJXIQO-PXRHQIMWSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- NZRWECQCBREPPG-UHFFFAOYSA-N NC(CCCCCCC(O)=O)=O Chemical compound NC(CCCCCCC(O)=O)=O NZRWECQCBREPPG-UHFFFAOYSA-N 0.000 description 1
- SGAGOYXFVKSXQZ-UHFFFAOYSA-N NCCCC#CCCCON Chemical compound NCCCC#CCCCON SGAGOYXFVKSXQZ-UHFFFAOYSA-N 0.000 description 1
- VYRYZZVHMBHTRR-CJLVFECKSA-N NCCOc(cc1)ccc1/C(/c(cc1)ccc1O)=C/c1ccccc1 Chemical compound NCCOc(cc1)ccc1/C(/c(cc1)ccc1O)=C/c1ccccc1 VYRYZZVHMBHTRR-CJLVFECKSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- JBTGHKUTYAMZEZ-UHFFFAOYSA-N cellocidin Chemical compound NC(=O)C#CC(N)=O JBTGHKUTYAMZEZ-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 150000001934 cyclohexanes Chemical group 0.000 description 1
- 150000001935 cyclohexenes Chemical class 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 150000001941 cyclopentenes Chemical class 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VDRNXRGWPDECQT-UHFFFAOYSA-N hexa-2,4-diynediamide Chemical compound NC(=O)C#CC#CC(N)=O VDRNXRGWPDECQT-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- LVJLBLBLYVXQEZ-NMSHJFGGSA-N methyl 8-[2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-methylamino]-8-oxooctanoate Chemical compound C1(=CC=CC=C1)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(OCCN(C(CCCCCCC(=O)OC)=O)C)C=C1 LVJLBLBLYVXQEZ-NMSHJFGGSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000005648 named reaction Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- ACKODFNIGGGCBA-UHFFFAOYSA-N spiro[3.3]heptane-2,6-dicarboxamide Chemical compound C1C(C(=O)N)CC21CC(C(N)=O)C2 ACKODFNIGGGCBA-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- FKLBCYXJZDLDLM-FGTMMUONSA-N tert-butyl N-[(2S)-1-[(2S,4R)-2-[(4-bromophenyl)methylcarbamoyl]-4-hydroxypyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate Chemical compound BrC1=CC=C(CNC(=O)[C@H]2N(C[C@@H](C2)O)C([C@H](C(C)(C)C)NC(OC(C)(C)C)=O)=O)C=C1 FKLBCYXJZDLDLM-FGTMMUONSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000006169 tetracyclic group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- compositions containing such compounds and their use in prevention and treatment of diseases and conditions.
- Estrogen Receptor alpha is a nuclear receptor that is activated by the hormone estrogen. Upon estrogen binding, Estrogen Receptor alpha undergoes a conformational change and dimerizes, which, along with other regulation factors, leads to a proliferation of cancerous cells. Approximately 75% of breast cancers express Estrogen Receptor alpha and exhibit estrogen- dependent proliferation. Morales, A.R., et al. Am. J. Clin. Path.2005; 123: 21- 27. Estrogen Receptor alpha is implicated in a variety of cancers, such as, but not limited to, breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, and esophageal cancer. Breast cancer is the most common cancer among women, and its incidence rate increases every year.
- SERMs selective estrogen receptor modulators
- SERMs are compounds that interact with intracellular Estrogen Receptors and act as agonists or antagonists. SERMs are used for treating various estrogen-related diseases, including breast cancer, infertility, ovulatory dysfunction, postmenopausal osteoporosis, estrogen-related gynecomastia, dyspareunia due to menopause, retroperitoneal fibrosis, and idiopathic sclerosing mesenteritis. It has also been reported that SERMs have beneficial effects on serum lipids in postmenopausal women.
- Tamoxifen is the most commonly used SERM and is widely used in treating Estrogen Receptor alpha positive breast cancer. Unfortunately, Tamoxifen activates other genes, which correlates with an increased incidence of other cancers, for example, endometrial cancer. Bernstein, L. et al. J. Natl Cancer Inst 1999; 91: 1654-62. Further, many cancer patients who receive Tamoxifen will eventually develop resistance. Ring, A. et al. Endocr Relat Cancer 2004; 11: 643-58. Upon failure of Tamoxifen treatment, patients may be prescribed Fulvestrant. Fulvestrant is a selective estrogen receptor degrader via proteasomal degradation.
- Tamoxifen competes with estrogen to bind to Estrogen Receptor alpha, whereas Fulvestrant is an antagonist. Fulvestrant’s effects are to degrade the Estrogen Receptor alpha protein as opposed to prevent
- Fulvestrant is an improvement over the deleterious effects of Tamoxifen, Fulvestrant suffers from poor drug-like properties, for example, poor bioavailability and intramuscular administration. Accordingly, there exists a need for an improved method of inhibiting cellular proliferation driven by Estrogen Receptor alpha. Fulvestrant’s mechanism of action, where the proteasome is engaged to degrade Estrogen Receptor alpha, provides an alternative mechanism to inhibiting Estrogen Receptor alpha driven cell proliferation. However, general proteasome degradation is not selective, and therefore could lead to deleterious effects. Accordingly, there is a need to discover and develop a drug that could lead to selective Estrogen Receptor alpha degradation, without the side effects caused by Tamoxifen or Fulvestrant.
- the present disclosure describes compounds that may be used to bind to both Estrogen Receptor alpha and a ubiquitin ligase.
- the compounds of the present disclosure possess two binding motifs conjugated via a linker.
- Estrogen Receptor alpha degradation may occur when both Estrogen Receptor alpha and a ubiquitin ligase are bound and brought into close proximity.
- X 1 is selected from CH 2 , NR 8 , O, and S;
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, hydroxy, and sulfhydryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 , R 7 , and R 8 are each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 9 is selected from H, C 1 -C 6 alkyl, halo, hydroxy, and sulfhydryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L* is a linker of 1 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(O), O, NR 4 , S, C 2 -alkenyl, C 2 - alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, and hydroxy, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 and R 7 is each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L is a linker of 6 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, and hydroxy, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ; each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 and R 7 are each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L 1 is a linker of 9 to 10 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. [11] In some embodiments,
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, and hydroxy, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ; each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 and R 7 are each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L 2 is a linker of 6 to 7 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. [13] In some embodiments, L 2 may be
- L may contain at least one O atom. In some embodiments, L may contain at least one aryl. In some embodiments, L may contain at least one C 2 -alkenyl. In some embodiments, L may contain at least one C 2 -alkynyl. In some embodiments, L may contain at least one 5- membered heteroaryl. In some embodiments, the at least one 5-membered heteroaryl may be a triazole.
- L 1 may contain at least one O atom. In some embodiments, L 1 may contain at least one aryl. In some embodiments, L 1 may contain at least one C 2 -alkenyl. In some embodiments, L 1 may contain at least one C 2 -alkynyl. In some embodiments, L 1 may contain at least one 5- membered heteroaryl. In some embodiments, the at least one 5-membered heteroaryl may be a triazole.
- L 2 may contain at least one O atom. In some embodiments, L 2 may contain at least one aryl. In some embodiments, L 2 may contain at least one C 2 -alkenyl. In some embodiments, L 2 may contain at least one C 2 -alkynyl. In some embodiments, L 2 may contain at least one 5- membered heteroaryl. In some embodiments, the at least one 5-membered heteroaryl may be a triazole.
- R 1 may be selected from halo and heteroaryl. In some embodiments, R 1 may be a 5-membered heteroaryl. In some embodiments, R 1 may be methylthiazole. In some embodiments, R 1 may be 4-methylthiazole. In some embodiments, R 1 may be .
- R 2 may be C 1 -C 6 alkyl. In some embodiments, R 2 may be tert-butyl. In some embodiments, R 2 may be iso- propyl.
- R 3 may be H. In some embodiments, R 3 may be C 1 -C 6 alkyl. In some embodiments, R 3 may be hydroxy.
- R 4 may be H. In some embodiments, R 4 may be C 1 -C 3 alkyl. In some embodiments, C 1 -C 3 may be methyl. In some embodiments, R 4 may be acyl. In some embodiments, the acyl may be acetyl.
- R 6 may be C 1 -C 3 alkyl. In some embodiments, the C 1 -C 3 alkyl may be methyl. In some embodiments, the R 6 may be H.
- R 7 may be selected from H and C 1 -C 3 alkyl. In some embodiments, R 7 may be H. In some embodiments, R 7 may be C 1 -C 3 alkyl. In some embodiments, the C 1 -C 3 alkyl may be methyl. [23] In some embodiments, provided herein is the compound:
- a pharmaceutical composition comprising the compound of Formulae (I), (II), (III), or (IV), and at least one additional component selected from pharmaceutically acceptable carriers, pharmaceutically acceptable vehicles, and pharmaceutically acceptable excipients.
- a pharmaceutical composition comprising the compound of Formulae (I), (II), (III), or (IV), and at least one additional component selected from pharmaceutically acceptable carriers, pharmaceutically acceptable vehicles, and pharmaceutically acceptable excipients.
- composition wherein the compound may be present in a therapeutically effective amount.
- provided herein is a method of treating cancer in a subject in need thereof, comprising administering to said subject an effective amount of the compound of Formulae (I), (II), (III), or (IV), or of the pharmaceutical composition provided herein, wherein the cancer may be chosen from breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, or esophageal cancer.
- the cancer may be breast cancer.
- the cancer may be positive for Estrogen Receptor alpha.
- the subject may have been previously treated with an anti-cancer agent.
- the anti- cancer agent may be tamoxifen.
- provided herein is a use of the compound of Formulae (I), (II), (III), or (IV) in a method of therapeutic treatment, wherein said therapeutic treatment may be treatment of breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, esophageal cancer, infertility, ovulatory dysfunction, postmenopausal osteoporosis, estrogen-related gynecomastia, dyspareunia due to menopause, retroperitoneal fibrosis, or idiopathic sclerosing mesenteritis.
- provided herein is a use of the compound of Formulae (I), (II), (III), or (IV) in the preparation of a medicament.
- provided herein is a method of inhibiting cell growth, comprising contacting a cell with the compound of Formulae (I), (II), or (III), or a pharmaceutical composition provided herein.
- the cell may be a cancer cell. In some embodiments, the cell may express Estrogen Receptor alpha.
- Figure 1A illustrates Compound 1 bound to Estrogen Receptor alpha and a Von Hippel-Lindau ligase
- Figure 1B is an alternative view of the protein-ligand complex illustrated in Figure 1A;
- Figure 2 illustrates the degradative activity of a compound of the present disclosure toward Estrogen Receptor alpha
- Figure 3A illustrates the comparative degradative activity of several compounds of the present disclosure toward Estrogen Receptor alpha
- Figure 3B illustrates the comparative degradative activity of several compounds of the present disclosure toward Estrogen Receptor alpha
- Figures 4A, 4B, and 4C show Estrogen Receptor alpha activity as a function of varying linker length
- Figure 5 illustrates a comparison of Estrogen Receptor alpha activity when cells are treated with compounds of high structural similarity
- Figure 6 illustrates the Estrogen Receptor alpha activity of cells after treatment with various compounds
- Figure 7 illustrates the time course of Estrogen Receptor alpha degradation induced by a compound of the present disclosure
- Figure 8 illustrates the time course of Estrogen Receptor alpha degradation induced by various compounds
- Figure 9A illustrates the proteasome-dependence of Estrogen Receptor alpha degradation
- Figure 9B illustrates the proteasome-dependence of Estrogen Receptor alpha degradation
- Figure 10A illustrates the anti-proliferation activity of a compound of the present disclosure toward the Estrogen Receptor alpha positive cell line MCF-7;
- Figure 10B illustrates the lack of anti-proliferation activity toward the triple negative (i.e., Estrogen Receptor alpha negative breast cancer MB- 231 cell line;
- Figure 11 illustrates the degradative activity of a compound of the present disclosure in another Estrogen Receptor alpha positive cell line T-47D;
- Figure 12 illustrates the plasma concentration of Compound 1 as a function of time after administration of various formulations
- Figure 13 illustrates the Estrogen Receptor alpha degradation in a tumor
- Figures 14A, 14B, and 14C show the effect of treatment on tumor weight and volume
- Figure 15A illustrates the effect on cell proliferation after administration of either Compound 1 or tamoxifen.
- Figure 15B illustrates the effect on Estrogen Receptor alpha degradation after administration of either Compound 1 or tamoxifen.
- cancer refers to diseases, disorders, and conditions that involve abnormal cell growth with the potential to invade or spread to other parts of the body.
- exemplary cancers include, but are not limited to, breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, and esophageal cancer.
- Subject refers to an animal, such as a mammal, that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful for both human therapy and veterinary applications. In one embodiment, the subject is a human.
- treatment refers to an amelioration of a disease or disorder, or at least one discernible symptom thereof.
- treatment refers to an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient.
- treatment or “treating” refers to inhibiting the progression of a disease or disorder, either physically, e.g., stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both.
- treatment or “treating” refers to delaying the onset of a disease or disorder. For example, treating a cholesterol disorder may comprise decreasing blood cholesterol levels.
- prevention or “preventing” refers to a reduction of the risk of acquiring a given disease or disorder.
- a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CN is attached through the carbon atom.
- acyl refers to R-C(O)- groups such as, but not limited to, (alkyl)-C(O)-, (alkenyl)-C(O)-, (alkynyl)-C(O)-, (aryl)-C(O)-, (cycloalkyl)-C(O)-, (heteroaryl)-C(O)-, and (heterocyclyl)-C(O)-, wherein the group is attached to the parent molecular structure through the carbonyl functionality.
- acyl radical which refers to the total number of chain or ring atoms of the, for example, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, or heteroaryl, portion plus the carbonyl carbon of acyl.
- a C 4 -acyl has three other ring or chain atoms plus carbonyl.
- alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C 2- C 8 )alkenyl.
- alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, and 4-(2-methyl-3-butene)-pentenyl.
- alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-8 carbon atoms, referred to herein as (C 1 -C 8 )alkyl.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2- propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1- propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2- pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl- 1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.
- “alkyl” is a straight-chain hydrocarbon.
- “alkyl” isopropyl
- alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C 2 - C 8 )alkynyl.
- alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4- propyl-2-pentynyl, and 4-butyl-2-hexynyl.
- aryl refers to a mono-, bi-, or other multi-carbocyclic, aromatic ring system with 5 to 14 ring atoms.
- the aryl group can optionally be fused to one or more rings selected from aryls, cycloalkyls, heteroaryls, and heterocyclyls.
- aryl groups of this present disclosure can be substituted with groups selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone.
- Exemplary aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl.
- Exemplary aryl groups also include, but are not limited to a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as“C 6 -aryl.”
- cycloalkyl refers to a saturated or unsaturated cyclic, bicyclic, or bridged bicyclic hydrocarbon group of 3-16 carbons, or 3-8 carbons, referred to herein as“(C 3 -C 8 )cycloalkyl,” derived from a cycloalkane.
- exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclohexenes, cyclopentanes, and cyclopentenes.
- Cycloalkyl groups may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
- Cycloalkyl groups can be fused to other cycloalkyl (saturated or partially unsaturated), aryl, or heterocyclyl groups, to form a bicycle, tetracycle, etc.
- the term“cycloalkyl” also includes bridged and spiro-fused cyclic structures which may or may not contain heteroatoms.
- the terms“halo” or“halogen” as used herein refer to -F, -Cl, -Br, and/or -I.
- heteroaryl refers to a mono-, bi-, or multi-cyclic, aromatic ring system containing one or more heteroatoms, for example 1-3 heteroatoms, such as nitrogen, oxygen, and sulfur. Heteroaryls can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
- Heteroaryls can also be fused to non-aromatic rings.
- Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, pyrimidilyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, furyl, phenyl, isoxazolyl, and oxazolyl.
- heteroaryl groups include, but are not limited to, a monocyclic aromatic ring, wherein the ring comprises 2-5 carbon atoms and 1-3 heteroatoms, referred to herein as "(C 2 -C 5 )heteroaryl.”
- heterocycle refers to a saturated or unsaturated 3- to 18-membered ring containing one, two, three, or four heteroatoms independently selected from nitrogen, oxygen, phosphorus, and sulfur.
- Heterocycles can be aromatic (heteroaryls) or non-aromatic.
- Heterocycles can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
- substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocycly
- Heterocycles also include bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from aryls, cycloalkyls, and heterocycles.
- Exemplary heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl,
- pharmaceutically acceptable carrier refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with
- compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
- composition refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
- prodrugs as used herein represents those prodrugs of the compounds of the present disclosure that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present disclosure.
- a discussion is provided in Higuchi et al., “Prodrugs as Novel Delivery Systems,” ACS Symposium Series, Vol.14, and in Roche, E.B., ed. Bioreversible Carriers in Drug Design, American
- compositions refers to salts of acidic or basic groups that may be present in compounds used in the present compositions.
- compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfate, citrate, matate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i
- salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
- the compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers.
- stereoisomers when used herein consist of all geometric isomers, enantiomers or
- stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated“( ⁇ )” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. In some embodiments, an enantiomer or stereoisomer may be provided substantially free of the corresponding enantiomer.
- the compound is a racemic mixture of (S)- and (R)-isomers.
- provided herein is a mixture of compounds wherein individual compounds of the mixture exist predominately in an (S)- or (R)-isomeric configuration.
- the compound mixture has an (S)-enantiomeric excess of greater than about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5%, or more.
- the compound mixture has an (S)-enantiomeric excess of greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about 90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or more.
- the compound mixture has an (R)- enantiomeric purity of greater than about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or more.
- the compound mixture has an (R)-enantiomeric excess of greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about 90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5% or more.
- Individual stereoisomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by: (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary; (2) salt formation employing an optically active resolving agent; or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
- Stereoisomeric mixtures can also be resolved into their component stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
- Stereoisomers can also be obtained from stereomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
- Geometric isomers can also exist in the compounds of the present disclosure.
- the present disclosure encompasses the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.
- Substituents around a carbon-carbon double bond are designated as being in the“Z” or“E” configuration wherein the terms“Z” and“E” are used in accordance with IUPAC standards.
- structures depicting double bonds encompass both the E and Z isomers.
- carbocyclic ring are designated as“cis” or“trans.”
- the term“cis” represents substituents on the same side of the plane of the ring and the term“trans” represents substituents on opposite sides of the plane of the ring.
- Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated“cis/trans.”
- structures described herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures except for the replacement of hydrogen by deuterium ( 2 H) or tritium ( 3 H), or the replacement of a carbon by a 13 C- or 14 C-carbon atom are within the scope of this disclosure.
- Such compounds may be useful as, for example, analytical tools, probes in biological assays, or therapeutic agents.
- X 1 is selected from CH 2 , NR 8 , O, and S;
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, hydroxy, and sulfhydryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 , R 7 , and R 8 are each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 9 is selected from H, C 1 -C 6 alkyl, halo, hydroxy, and sulfhydryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L* is a linker of 1 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(O), C(NH), C(S), O, NR 4 , S, C 2 - alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, and hydroxy, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 and R 7 are each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L is a linker of 6 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, and hydroxy, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 and R 7 are each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L 1 is a linker of 9 to 10 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- R 1 is selected from H, C 1 -C 6 alkyl, halo, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 2 is selected from H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 3 is selected from H, C 1 -C 6 alkyl, halo, and hydroxy, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- R 4 is selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- each R 5 is independently selected from C 1 -C 6 alkyl, halo, cyano, and hydroxy;
- R 6 and R 7 are each independently selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 ;
- L 2 is a linker of 6 to 7 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may range from 1 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(O), C(NH), C(S), O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L* may range from about 6 carbon atoms to about 16 carbon atoms, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may range from about 6 carbon atoms to about 11 carbon atoms, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L* may range from about 6 carbon atoms to about 9 carbon atoms, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may be 6 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 - alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L* may be 7 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may be 8 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L* may be 9 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may be 10 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L* may be 11 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 - alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may be 12 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L* may be 13 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may be 14 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 - alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L* may be 15 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may be 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L* may be 1 carbon atom in length. In some embodiments, L* may be 2 carbon atoms in length. In some
- L* may be 3 carbon atoms in length. In some embodiments, L* may be 4 carbon atoms in length. In some embodiments, L* may be 5 carbon atoms in length. In some embodiments, L* may be 6 carbon atoms in length. In some embodiments, L* may be 7 carbon atoms in length. In some
- L* may be 8 carbon atoms in length. In some embodiments, L* may be 9 carbon atoms in length. In some embodiments, L* may be 10 carbon atoms in length. In some embodiments, L* may be 11 carbon atoms in length. In some embodiments, L* may be 12 carbon atoms in length. In some embodiments, L* may be 13 carbon atoms in length. In some embodiments, L* may be 14 carbon atoms in length. In some embodiments, L* may be 15 carbon atoms in length. In some embodiments, L* may be 16 carbon atoms in length.
- L* may be 6 carbon atoms in length, wherein 2 carbon atoms have been replaced by O. In some embodiments, L* may be 8 carbon atoms in length, wherein 2 carbon atoms have been replaced by O. In some embodiments, L* may be 9 carbon atoms in length, wherein 3 carbon atoms have been replaced by O. In some embodiments, L* may be 11 carbon atoms in length, wherein 3 carbon atoms have been replaced by O. In some embodiments, L* may be 14 carbon atoms in length, wherein 4 carbon atoms have been replaced by O. In some embodiments, L* may be 15 carbon atoms in length, wherein 5 carbon atoms have been replaced by O.
- L* may be 1 carbon atom in length, wherein the one carbon atom is optionally replaced by a cycloalkyl. In some embodiments, L* may be 1 carbon atom in length, wherein the one carbon atom is optionally replaced by a heterocycle. In some embodiments, L* may be 1 carbon atom in length, wherein the one carbon atom is optionally replaced by an aryl. In some embodiments, L* may be 1 carbon atom in length, wherein the one carbon atom is optionally replaced by a heteroaryl. In some embodiments, L* may be 1 carbon atom in length, wherein the one carbon atom is optionally replaced by a C 2 -alkenyl. In some embodiments, L* may be 1 carbon atom in length, wherein the one carbon atom is optionally replaced by a C 2 -alkynyl.
- L* may be 2 carbon atoms in length, wherein one carbon atom is optionally replaced by a cycloalkyl. In some embodiments, L* may be 2 carbon atoms in length, wherein one carbon atom is optionally replaced by a heterocycle. In some embodiments, L* may be 2 carbon atoms in length, wherein one carbon atom is optionally replaced by an aryl. In some embodiments, L* may be 2 carbon atoms in length, wherein one carbon atom is optionally replaced by a heteroaryl.
- L* may be 3 carbons in length, wherein one carbon atom is optionally replaced by a C 2 -alkenyl. In some embodiments, L* may be 4 carbon atoms in length, wherein one carbon atom is optionally replaced by a C 2 -alkenyl. In some embodiments, L* may be 5 carbon atoms in length, wherein one carbon atom is optionally replaced by a C 2 -alkenyl. In some embodiments, L* may be 6 carbon atoms in length, wherein one carbon atom is optionally replaced by a C 2 -alkenyl.
- L* may be 3 carbons in length, wherein one carbon atom is optionally replaced by a C 2 - alkynyl. In some embodiments, L* may be 4 carbon atoms in length, wherein one carbon atom is optionally replaced by a C 2 -alkynyl. In some embodiments, L* may be 5 carbon atoms in length, wherein one carbon atom is optionally replaced by a C 2 -alkynyl. In some embodiments, L* may be 6 carbon atoms in length, wherein one carbon atom is optionally replaced by a C 2 -alkynyl.
- L* may be 4 carbon atoms in length, wherein two carbon atoms are each optionally replaced by a C 2 -alkenyl. In some embodiments, L* may be 5 carbon atoms in length, wherein two carbon atoms are each optionally replaced by a C 2 -alkenyl. In some embodiments, L* may be 6 carbon atoms in length, wherein two carbon atoms are each optionally replaced by a C 2 -alkenyl. In some embodiments, L* may be 4 carbon atoms in length, wherein two carbon atoms are each optionally replaced by a C 2 -alkynyl.
- L* may be 5 carbon atoms in length, wherein two carbon atoms are each optionally replaced by a C 2 -alkynyl. In some embodiments, L* may be 6 carbon atoms in length, wherein two carbon atoms are each optionally replaced by a C 2 -alkynyl.
- L* may be 4 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 5 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 6 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O).
- L* may be 7 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 8 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 9 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O).
- L* may be 10 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 11 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 12 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O).
- L* may be 13 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 14 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O). In some embodiments, L* may be 15 carbon atoms in length, wherein a first carbon atom is optionally replaced by O or NR 4 and a second carbon atom is optionally replaced by C(O).
- L* may be selected from L, L 1 , and L 2 . In some embodiments, L* may be L. In some embodiments, L* may be L 1 . In some embodiments, L* may be L 2 . [93] In some embodiments, L* may be In some embodiments, L* may be . In some embodiments, L* may be n some embodiments, L* may be In some embodiments, L* may be
- L* may be . In some embodiments, L* may be
- L* may be
- L* may be
- L* may be . In some embodiments, L* may be . In some embodiments, L* may be In some embodiments, L* may be In some embodiments, L* may be . In some embodiments, L* may be In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L*, L* may be . In some embodiments, L*, L* may be . In some embodiments, L*, L* may be . In some embodiments, L*, L* may be . In some embodiments, L*, L*
- L* may be .
- L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some
- L* may be . In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be In some embodiments, L* may be . In some embodiments, L* may be . In some embodiments, L* may be
- X 1 may be selected from CH 2 , NR 8 , O, and S. In some embodiments, X 1 may be CH 2 . In some embodiments, X 1 may be NR 8 . In some embodiments, X 1 may be O. In some embodiments, X 1 may be S.
- R 8 may be selected from H, C 1 -C 6 alkyl, and acyl, each of which may be substituted with 0, 1, 2, or 3 R 5 .
- R 8 may be selected from H, C 1 -C 6 alkyl, and acyl.
- R 8 may be H.
- R 8 may be C 1 -C 6 alkyl, substituted with 0, 1, 2, or 3 R 5 .
- R 8 may be C 1 -C 6 alkyl.
- R 8 may be C 1 alkyl.
- R 8 may be C 1 alkyl, substituted with 0, 1, 2, or 3 R 5 .
- R 8 may be acyl.
- R 8 may be acyl, substituted with 0, 1, 2, or 3 R 5 .
- R 9 may be selected from H, C 1 -C 6 alkyl, halo, hydroxy, and sulfhydryl, each of which is substituted with 0, 1, 2, or 3 R 5 .
- R 9 may be H.
- R 9 may be halo.
- R 9 may be halo, where the halo is fluoro.
- R 9 may be halo, where the halo is chloro.
- R 9 may be hydroxy.
- R 9 may be sulfhydryl.
- R 9 may be C 1 -C 6 alkyl. In some embodiments, R 9 may be C 1 alkyl. In some embodiments, R 9 may be C 1 alkyl, substituted with 0, 1, 2, or 3 R 5 . In some embodiments, R 9 may be C 1 alkyl.
- L may range from about 6 carbon atoms to about 16 carbon atoms, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L may range from about 6 carbon atoms to about 16 carbon atoms, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may range from about 6 carbon atoms to about 11 carbon atoms, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L may range from about 6 carbon atoms to about 9 carbon atoms, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may be 6 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 - alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L may be 7 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may be 8 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may be 9 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may be 10 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L may be 11 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may be 12 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L may be 13 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 - alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may be 14 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. In some embodiments, L may be 15 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 -alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
- L may be 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by O, NR 4 , S, C 2 - alkenyl, C 2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl. [101] In some embodiments, L may be 6 carbon atoms in length. In some embodiments, L may be 7 carbon atoms in length. In some
- L may be 8 carbon atoms in length. In some embodiments, L may be 9 carbon atoms in length. In some embodiments, L may be 10 carbon atoms in length. In some embodiments, L may be 11 carbon atoms in length. In some embodiments, L may be 12 carbon atoms in length. In some embodiments, L may be 13 carbon atoms in length. In some embodiments, L may be 14 carbon atoms in length. In some embodiments, L may be 15 carbon atoms in length. In some embodiments, L may be 16 carbon atoms in length.
- L may be 6 carbon atoms in length, wherein 2 carbon atoms have been replaced by O. In some embodiments, L may be 8 carbon atoms in length, wherein 2 carbon atoms have been replaced by O. In some embodiments, L may be 9 carbon atoms in length, wherein 3 carbon atoms have been replaced by O. In some embodiments, L may be 11 carbon atoms in length, wherein 3 carbon atoms have been replaced by O. In some embodiments, L may be 14 carbon atoms in length, wherein 4 carbon atoms have been replaced by O. In some embodiments, L may be 15 carbon atoms in length, wherein 5 carbon atoms have been replaced by O.
- R 1 may be C 1 -C 6 alkyl. In some embodiments, R 1 may be methyl. In some embodiments, R 1 may be ethyl. In some embodiments, R 1 may be iso-propyl. In some embodiments, R 1 may be tert-butyl.
- R 1 may be heterocycle. In some embodiments, R 1 may be heteroaryl. In some embodiments, R 1 may be a 5- membered heteroaryl. In some embodiments, R 1 may be thiazole. In some embodiments, R 1 may be oxazole. In some embodiments, R 1 may be a 5- membered heteroaryl substituted with 1 R 5 . In some embodiments, R 1 may be a 5-membered heteroaryl substituted with 1 R 5 , wherein the R 5 is methyl. In some embodiments, R 1 may be thiazole substituted with 1 R 5 . In some embodiments, R 1 may be thiazole substituted with 1 R 5 , wherein the R 5 is methyl. In some embodiments, R 1 may be . In some embodiments, R 1 may be pyrimidine.
- R 1 may be halo. In some embodiments, R 1 may be fluoro. In some embodiments, R 1 may be chloro. In some embodiments, R 1 may be bromo. In some embodiments, R 1 may be iodo. In some embodiments, R 1 may be H.
- R 2 may be H. In some embodiments, R 2 may be C 1 -C 6 alkyl. In some embodiments, R 2 may be C 1 -C 3 alkyl. In some embodiments, R 2 may be C 2 -C 4 alkyl. In some embodiments, R 2 may be methyl. In some embodiments, R 2 may be ethyl. In some embodiments, R 2 may be iso-propyl. In some embodiments, R 2 may be tert-butyl.
- R 2 may be C 3 -C 6 cycloalkyl. In some embodiments, R 2 may be cyclopropyl. In some embodiments, R 2 may be cyclobutyl. In some embodiments, R 2 may be cyclopentyl. In some
- R 2 may be cyclohexyl.
- R 3 may be H. In some embodiments, R 3 may be hydroxy. In some embodiments, R 3 may be C 1 -C 6 alkyl. In some embodiments, R 3 may be C 1 -C 4 alkyl. In some embodiments, R 3 may be methyl. In some embodiments, R 3 may be ethyl. In some embodiments, R 3 may be iso-propyl. In some embodiments, R 3 may be tert-butyl.
- R 3 may be halo. In some embodiments, R 3 may be fluoro. In some embodiments, R 3 may be chloro. In some embodiments, R 3 may be chloro. In some embodiments, R 3 may be bromo. In some embodiments, R 3 may be iodo.
- R 4 may be H. In some embodiments, R 4 may be C 1 -C 6 alkyl. In some embodiments, R 4 may be C 1 -C 3 alkyl. In some embodiments, R 4 may be methyl. In some embodiments, R 4 may be acyl. In some embodiments, R 4 may be acetyl.
- R 5 may be C 1 -C 6 alkyl. In some embodiments, R 5 may be C 1 -C 4 alkyl. In some embodiments, R 5 may be methyl. In some embodiments, R 5 may be ethyl. In some embodiments, R 5 may be iso-propyl. In some embodiments, R 5 may be tert-butyl.
- R 5 may be halo. In some embodiments, R 5 may be fluoro. In some embodiments, R 5 may be chloro. In some embodiments, R 5 may be bromo. In some embodiments, R 5 may be iodo.
- R 6 may be selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 .
- R 6 may be H. In some membodiments, R 6 may be C 1 -C 6 alkyl. In some embodiments, R 6 may be C 1 -C 3 alkyl. In some embodiments, R 6 may be methyl. In some embodiments, R 6 may be acyl. In come embodiments, R 6 may be C 1 -C 3 acyl. In come embodiments, R 6 may be acetyl.
- R 7 may be selected from H, C 1 -C 6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R 5 .
- R 7 may be H.
- R 7 may be C 1 -C 6 alkyl.
- R 7 may be C 1 -C 3 alkyl.
- R 7 may be C 1 -C 3 alkyl.
- R 7 may be methyl.
- R 7 may be C 1 -C 3 acyl.
- R 7 may be acetyl.
- L may be In some embodiments, L may be . In some embodiments, L may be . In some embodiments, L may be
- L 1 may be
- L 1 may be In some embodiments, L 1 may be In some embodiments, L 1 may be In some embodiments, L 1 may be In some embodiments, L 1 may be In some embodiments, L 1 may be In some embodiments, L 1 may be
- L 2 may be . In some embodiments, L 2 . In
- L 2 may be . In some embodiments, L 2
- the compound 4-(5- (((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5- oxopentyl)benzyl (2-(4-((Z)-1,2-diphen
- the compound 6-(2- (((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2- oxoethoxy)hex-4-yn-1-yl (2-
- N1- (3-((2-(4-((Z)-1,2-bis(4-hydroxyphenyl)but-1-en-1- yl)phenoxy)ethyl)(methyl)amino)-3-oxopropyl)-N4-((S)-1-((2S,4R)-4-hydroxy-2- ((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1- oxobutan-2-yl)succinamide.
- compositions of the present disclosure comprise at least one compound of Formulae (I), (II), (III), or (IV), or tautomer,
- stereoisomer, pharmaceutically acceptable salt or hydrate thereof formulated together with one or more pharmaceutically acceptable carriers include those suitable for oral, rectal, topical, buccal and parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) administration.
- parenteral e.g., subcutaneous, intramuscular, intradermal, or intravenous
- the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used.
- Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of a compound of the present disclosure as powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
- such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association at least one compound of the present disclosure as the active compound and a carrier or excipient (which may constitute one or more accessory ingredients).
- the carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient.
- the carrier may be a solid or a liquid, or both, and may be formulated with at least one compound described herein as the active compound in a unit-dose formulation, for example, a tablet, which may contain from about 0.05% to about 95% by weight of the at least one active compound.
- a unit-dose formulation for example, a tablet, which may contain from about 0.05% to about 95% by weight of the at least one active compound.
- Other pharmacologically active substances may also be present including other compounds.
- the formulations of the present disclosure may be prepared by any of the well-known techniques of pharmacy consisting essentially of admixing the components.
- liquid compositions conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
- Liquid pharmacologically administrable compositions can, for example, be prepared by, for example, dissolving or dispersing, at least one active compound of the present disclosure as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
- suitable formulations may be prepared by uniformly and intimately admixing the at least one active compound of the present disclosure with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product.
- a tablet may be prepared by compressing or molding a powder or granules of at least one compound of the present disclosure, which may be optionally combined with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing, in a suitable machine, at least one compound of the present disclosure in a free-flowing form, such as a powder or granules, which may be optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s).
- Molded tablets may be made by molding, in a suitable machine, where the powdered form of at least one compound of the present disclosure is moistened with an inert liquid diluent.
- Formulations suitable for buccal (sub-lingual) administration include lozenges comprising at least one compound of the present disclosure in a flavored base, usually sucrose and acacia or tragacanth, and pastilles comprising the at least one compound in an inert base such as gelatin and glycerin or sucrose and acacia.
- Formulations of the present disclosure suitable for parenteral administration comprise sterile aqueous preparations of at least one compound of Formulae (I), (II), or (III), or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof, which are approximately isotonic with the blood of the intended recipient.
- These preparations are administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection.
- Such preparations may conveniently be prepared by admixing at least one compound described herein with water and rendering the resulting solution sterile and isotonic with the blood.
- Injectable compositions according to the present disclosure may contain from about 0.1 to about 5% w/w of the active compound.
- Formulations suitable for rectal administration are presented as unit-dose suppositories. These may be prepared by admixing at least one compound as described herein with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
- Formulations suitable for topical application to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
- Carriers and excipients which may be used include Vaseline, lanoline, polyethylene glycols, alcohols, and combinations of two or more thereof.
- the active compound i.e., at least one compound of Formulae (I), (II), (III), or (IV), or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof
- the active compound i.e., at least one compound of Formulae (I), (II), (III), or (IV), or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof
- the amount of active compound administered may be dependent on the subject being treated, the subject's weight, the manner of administration and the judgment of the prescribing physician.
- a dosing schedule may involve the daily or semi-daily administration of the encapsulated compound at a perceived dosage of about 1 ⁇ g to about 1000 mg.
- intermittent administration such as on a monthly or yearly basis, of a dose of the encapsulated compound may be employed.
- Encapsulation facilitates access to the site of action and allows the administration of the active ingredients simultaneously, in theory producing a synergistic effect.
- physicians will readily determine optimum dosages and will be able to readily modify administration to achieve such dosages.
- a therapeutically effective amount of a compound or composition disclosed herein can be measured by the therapeutic effectiveness of the compound.
- the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being used.
- the therapeutically effective amount of a disclosed compound is sufficient to establish a maximal plasma
- Preliminary doses as, for example, determined according to animal tests, and the scaling of dosages for human administration is performed according to art-accepted practices.
- Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
- Compositions that exhibit large therapeutic indices are preferable.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- a therapeutically effective amount may vary with the subject's age, condition, and gender, as well as the severity of the medical condition in the subject.
- the dosage may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof is administered to treat cancer in a subject in need thereof.
- the cancer is chosen from breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, and esophageal cancer.
- the cancer is breast cancer.
- the cancer is lung cancer.
- the cancer is ovarian cancer.
- the cancer is endometrial cancer.
- the cancer is prostate cancer.
- the cancer is esophageal cancer.
- the cancer is positive for Estrogen Receptor alpha.
- a compound of Formulae (I), (II), or (III), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof is administered as a pharmaceutical composition.
- the subject has been previously treated with tamoxifen.
- the therapeutic treatment is for the treatment of breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, and esophageal cancer.
- the therapeutic treatment is for the treatment of breast cancer.
- the therapeutic treatment is for lung cancer.
- the therapeutic treatment is for the treatment of ovarian cancer.
- the therapeutic treatment is for the treatment of endometrial cancer.
- the therapeutic treatment is for the treatment of prostate cancer.
- the therapeutic treatment is for the treatment of esophageal cancer. In some embodiments, the therapeutic treatment is for the treatment of estrogen-related diseases and conditions. In some embodiments, the therapeutic treatment is for the treatment of infertility. In some embodiments, the therapeutic treatment is for the treatment of ovulatory dysfunction. In some embodiments, the therapeutic treatment is for the treatment of postmenopausal osteoporosis. In some embodiments, the therapeutic treatment is for the treatment of estrogen-related gynecomastia. In some embodiments, the therapeutic treatment is for the treatment of dyspareunia due to menopause. In some embodiments, the therapeutic treatment is for the treatment of
- the therapeutic treatment is for the treatment of idiopathic sclerosing mesenteritis.
- a method of inhibiting cell growth comprising contacting a cell with a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof.
- the cell may express Estrogen Receptor alpha.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof is administered in combination with another therapeutic agent.
- the other therapeutic agent can provide additive or synergistic value relative to the administration of a compound of the present disclosure alone.
- the therapeutic agent can be selected from, for example, hormones and hormonal analogues; signal transduction pathway inhibitors; topoisomerase I inhibitors;
- the therapeutic agent may be a hormone or hormonal analogue.
- the therapeutic agent may be a signal transduction pathway inhibitor.
- the therapeutic agent may be a topoisomerase I inhibitor.
- the therapeutic agent may be a hormone or hormonal analogue.
- the therapeutic agent may be a signal transduction pathway inhibitor.
- the therapeutic agent may be a topoisomerase I inhibitor.
- therapeutic agent may be a topoisomerase II inhibitor.
- the therapeutic agent may be an antimetabolite neoplastic agent.
- the therapeutic agent may be an antibiotic neoplastic agent.
- the therapeutic agent may be an alkylating agent.
- the therapeutic agent may be an anti-microtubule agent.
- the therapeutic agent may be a platinum coordination complex.
- the therapeutic agent may be an aromatase inhibitor.
- the therapeutic agent may be an anti-mitotic agent.
- the aromatase inhibitor may be selected from anastrazole, letrozole, vorozole, fadrozole, exemestane, and formestane.
- the aromatase inhibitor is anastrazole.
- the aromatase inhibitor may be letrozole.
- the aromatase inhibitor may be vorozole.
- the aromatase inhibitor may be fadrozole.
- the aromatase inhibitor may be exemestane.
- the aromatase inhibitor may be formestane.
- the anti-mitotic agent may be selected from paclitaxel, docetaxel, and Abraxane.
- the anti- mitotic agent may be paclitaxel.
- the anti-mitotic agent may be docetaxel.
- the anti-mitotic agent may be Abraxane.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with a hormone or hormonal analog.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with a signal transduction pathway inhibitor.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with an antimetabolite neoplastic agent.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with a topoisomerase I inhibitor.
- a compound of Formulae (I), (II), (III), (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with a topoisomerase II inhibitor.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with an aromatase inhibitor.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with one or more anti-cancer agents.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with an anti-cancer agent, wherein the anti-cancer agent is tamoxifen.
- a compound of Formulae (I), (II), (III), or (IV), or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof may be administered in combination with an anti-cancer agent, wherein the anti-cancer agent is fulvestrant.
- the chemical entities described herein can be synthesized according to one or more illustrative schemes herein and/or techniques well known in the art. Unless specified to the contrary, the reactions described herein take place at atmospheric pressure, generally within a temperature range from about -10° C to about 200° C. Further, except as otherwise specified, reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about -10° C to about 200° C over a period that can be, for example, about 1 to about 24 hours; reactions left to run overnight in some embodiments can average a period of about 16 hours.
- protecting groups for sensitive or reactive groups may be employed where necessary, in accordance with general principles of chemistry.
- Protecting groups are manipulated according to standard methods of organic synthesis (T.W. Greene and P.G.M. Wuts (1999) Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons). These groups may be removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
- the (R)- and (S)-isomers of the nonlimiting exemplary compounds can be resolved by methods known to those skilled in the art, for example, by formation of diastereoisomeric salts or complexes which can be separated, e.g., by crystallization; via formation of diastereoisomeric derivatives which can be separated, e.g., by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, e.g., enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, e.g., on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent.
- a chiral environment e.g., on a chiral support, such as silica with a bound chiral ligand
- a specific enantiomer can be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
- the compounds described herein can be optionally contacted with a pharmaceutically acceptable acid to form the corresponding acid addition salts. Also, the compounds described herein can be optionally contacted with a pharmaceutically acceptable base to form the corresponding basic addition salts.
- disclosed compounds can generally be synthesized by an appropriate combination of generally well-known synthetic methods. Techniques useful in synthesizing these chemical entities are both readily apparent and accessible to those of skill in the relevant art, based on the instant disclosure. Many of the optionally substituted starting compounds and other reactants are commercially available, e.g., from Aldrich Chemical
- DMEM Dulbecco’s Modification of Eagle’s Medium 4.
- DMSO dimethylsulfoxide
- FBS fetal bovine serum
- MCF-7 Michigan Cancer Foundation-7 breast cancer cell line 17.
- NMR nuclear magnetic resonance
- PVDF polyvinylidene fluoride
- SDS sodium dodecyl sulfate
- Example 1 was purified by reverse- phase preparative HPLC to afford Example 1 as a white solid (220 mg, 57%).
- Example 2 (71 mg, 48%) as a white solid.
- N 1 -(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N 4 -((S)- 1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N 1 - methylsuccinamide Obtained as a white solid (20 mg, 82%).
- N 1 -(2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)-N 6 -((S)- 1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N 1 - methyladipamide Obtained as a white solid (20 mg, 80%).
- MCF-7 cells were maintained in high glucose DMEM (Corning cellgro, 15-013-CM), supplemented with 10% FBS, 1X L-Glutamine (29.2 mg/mL) and 1X Penicillin Streptomycin (10,000 I.U./mL Penicillin; 10,000 ⁇ g/mL Streptomycin; Corning, 30-009-CI).
- the resulting MCF-7 cells were plated into a 24-well plate at 1 ⁇ 10 5 cells/well, and the following day, compound was added to the cell medium at various concentrations. After treating the cell medium with compound, the cell plates were incubated for 20 hours at 37° C. Upon cooling, cells were lysed by addition of SDS loading buffer.
- the resulting cell lysates were subjected to immunoblotting by standard protocol. with primary antibodies of mouse anti-human ER ⁇ monoclonal antibody (Santa Cruz Biotechnology Inc., #SC-8002) and 1:1000 goat anti-human actin polyclonal antibody (Santa Cruz Biotechnology Inc. #SC-1616). Western blot results visualized using
- the membranes were then incubated with Primary antibodies mouse anti-ER ⁇ (1:500, Santa Cruz Biotechnology), or goat anti- actin (1:4,000, Santa Cruz Biotechnology) overnight at 4° C, followed by washing 3 times with TBST, and then incubated with horseradish peroxidase– conjugated rabbit anti-mouse or anti-goat IgG (1:5,000) for 1 hour. After TBST washes, blots were developed with an enhanced chemiluminescence kit (Thermo Fisher Scientific). The bands were imaged by chemidock touch system (Bio-Rad) and quantified by ImageJ.
- FIG.4A shows Estrogen Receptor alpha degradation as a function of linker length for compounds of the formula: .
- FIG.4B shows Estrogen Receptor alpha degradation as a function of linker length for compounds of the formula:
- FIG.4C shows the relationship between Estrogen Receptor alpha degradation IC 50 and linker length.
- Table 3 contains the IC 50 values depicted in FIG.4C:
- Estrogen Receptor alpha was studied. It was surprisingly found that the presence of the carbonyl adjacent to the tamoxifen moiety is critical, as shown in FIG.5. Compound B was found to be ten-fold more potent than Compound A, lacking the critical carbonyl group. Example 6. Comparison of Estrogen Receptor alpha degradation activity of compounds of the present disclosure and various literature compounds.
- MCF-7 cells were treated with compounds A, B, and C, as described in Example 5. As shown in FIG.5, compound A, of the present disclosure, is more potent than both compounds B and C.
- MCF-7 cells were maintained in high glucose DMEM (Corning cellgro, 15-013-CM), supplemented with 10% FBS, 1x L-Glutamine (29.2 mg/mL), and Penicillin Streptomycin (10,000 I.U./mL Penicillin; 10,000 ⁇ g/mL Streptomycin; Corning, 30-009-CI). These cells were then plated into 24-well plate at 1 ⁇ 10 5 cells/well, and Compound 1 was added to each well of the 24- well plate at a final concentration of 100 nM the following day. The cells were lysed at 1, 2, 4, 8, 24, and 48 hours.
- FIG.7 depicts the degradative activity of Compound 1 at various time points over the course of 48 hours.
- Estrogen Receptor alpha as a function of time, is shown in FIG.8, for compounds A-D.
- MCF-7 cells were maintained in high glucose DMEM (Corning cellgro, 15-013-CM) supplemented with 10% FBS, 1x L-Glutamine (29.2 mg/mL), and Penicilin Streptomycin (10,000 I.U./mL Penicillin; 10,000 ⁇ g/mL Streptomycin; Corning, 30-009-CI). These cells were plated into 24-well plates at 1 ⁇ 10 5 cells/well, and the following day Compound 1 (
- FIG.9A illustrates the proteasome dependence of Estrogen Receptor alpha degradation induced by compounds of the present disclosure.
- FIG.9B shows the effect of treatment using Compound 1 alone and in the presence of tamoxifen and expomicin, at 100 nM, 10 ⁇ M, and 1 ⁇ M respectively.
- Example 9 Compounds of the present disclosure demonstrate selectivity for cells with Estrogen Receptor alpha.
- MCF-7 cells were maintained in high glucose DMEM (Corning cellgro, 15-013-CM) supplemented with 10% FBS, 1x L-Glutamine (29.2 mg/mL), and Penicilin Streptomycin (10,000 I.U./mL Penicillin; 10,000 ⁇ g/mL Streptomycin; Corning, 30-009-CI). These cells were plated into 24-well plates at 2 ⁇ 10 4 cells/well, and the following day Compound 1 (
- FIGS.10A and 10B demonstrate the compounds of the present disclosure for cells that are selective for Estrogen Receptor alpha positive (10A) over Estrogen Receptor alpha negative (10B).
- Example 10 Compounds of the present disclosure are active against other cell types that are positive for Estrogen Receptor alpha.
- T47D cells were maintained in RPMI 1640 , supplemented with 10% FBS, 1x L-Glutamine (29.2 mg/mL), and Penicillin Streptomycin (10,000 I.U./mL Penicillin; 10,000 ⁇ g/mL Streptomycin; Corning, 30-009-CI) and 5 ⁇ g/mL Bovine insulin.
- the resulting T47D cells were plated into a 24-well plate at 1 ⁇ 10 5 cells/well, and the following day, compound was added to the cell medium at various concentrations. After treating the cell medium with compound, the cell plates were incubated for 20 hours. Upon cooling, cells were lysed. The resulting cell lysates were subjected to immunoblotting by standard protocol with primary antibodies of mouse anti-human ER ⁇
- FIG.11 shows the effect induce by Compound 1 on Estrogen Receptor alpha degradation at various concentrations.
- Example 11 Pharmacokinetic study of a compound of the present disclosure.
- mice Nine mice were divided into three groups, with three mice per group. Each mouse was orally administered one of the formulations described above, at 50 mg/kg. The dosing volume administered was 10 mL/kg. Group 1 was administered Formulation 1, and the mice in group 1 were in a fed state. Group 2 was administered Formulation 2, and the mice in group 2 were in a fasted state. Group 3 was administered Formulation 3, and the mice in group 3 were in a fed state.
- FIG.12 shows that administration of Formulations 1 and 2 resulted in appreciable amounts of Compound 1 in the blood at the 4 hour time point.
- Table 7 shows the pharmacokinetic parameters for the various formulations.
- Example 12 Measurement of Estrogen Receptor alpha expression in MCF-7 breast cancer xenograft model.
- mice Female BALB/c nude mice (with supplemental 17- ⁇ estradiol) bearing MCF-7 tumors (mean tumor volume 200 mm 3 ) were treated with Compound 1 (5 mg/kg, 3 doses/day, i.p.) in vehicle or by vehicle only for 1 day.
- vehicle solution is: 10% Ethanol, 20% Solutol, 20% PG, 50% Captisol.
- tumor tissues from each animal were collected and subjected to western blot analysis for ER ⁇ and Actin.
- Example 13 Compounds of the present disclosure inhibit cancer cell growth in a MCF-7 breast cancer-derived mouse xenograft model.
- mice Female BALB/c nude mice (supplemented with 17- ⁇ estradiol) bearing MCF-7 tumors (mean tumor volume was 211 mm 3 ) were treated with
- tumor volume [length ⁇ width 2 ]/2)
- FIG.14A shows a significant decrease in tumor weight for the mice in the treatment group versus the mice in the control group.
- FIGS.14B and 14C show tumor volume and tumor volume percent change, respectively, as a function of time for the mice in the treatment group versus mice in the control group.
- Example 14 Assessment of compound activity in tamoxifen-resistant tumor cells
- Compound 1 was compared with that of tamoxifen and fulvestrant. LTED cells were plated into 96-well plates at 0.3 ⁇ 10 4 cells/well and assayed for 4 days. Compounds were added to medium at different final concentrations as indicated in the results. Media were replaced each day during compound exposure.
- FIG.15A shows change in cell number as a function of inhibitor concentration.
- FIG.15B shows change in Estrogen Receptor alpha expression as a function of inhibitor concentration.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020197003884A KR20190039125A (ko) | 2016-07-12 | 2017-07-11 | 신규한 화합물 및 이의 용도 |
JP2019522609A JP2019525955A (ja) | 2016-07-12 | 2017-07-11 | 新規化合物およびその使用 |
CA3030411A CA3030411A1 (fr) | 2016-07-12 | 2017-07-11 | Nouveaux composes et leurs utilisations |
EP17828300.8A EP3368011A4 (fr) | 2016-07-12 | 2017-07-11 | Nouveaux composés et leurs utilisations |
CN201780001677.9A CN108495618B (zh) | 2016-07-12 | 2017-07-11 | 新的化合物及其用途 |
AU2017297344A AU2017297344A1 (en) | 2016-07-12 | 2017-07-11 | Novel compounds and uses thereof |
HK18116445.7A HK1257296A1 (zh) | 2016-07-12 | 2018-12-21 | 新的化合物及其用途 |
HK18116500.9A HK1257539A1 (zh) | 2016-07-12 | 2018-12-24 | 新的化合物及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361263P | 2016-07-12 | 2016-07-12 | |
US62/361,263 | 2016-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018013559A1 true WO2018013559A1 (fr) | 2018-01-18 |
Family
ID=60942054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/041526 WO2018013559A1 (fr) | 2016-07-12 | 2017-07-11 | Nouveaux composés et leurs utilisations |
Country Status (10)
Country | Link |
---|---|
US (3) | US9944632B2 (fr) |
EP (1) | EP3368011A4 (fr) |
JP (1) | JP2019525955A (fr) |
KR (1) | KR20190039125A (fr) |
CN (2) | CN108495618B (fr) |
AU (1) | AU2017297344A1 (fr) |
CA (1) | CA3030411A1 (fr) |
HK (2) | HK1257296A1 (fr) |
MA (1) | MA43141A (fr) |
WO (1) | WO2018013559A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020142227A1 (fr) * | 2019-01-03 | 2020-07-09 | The Regents Of The University Of Michigan | Agents de dégradation de protéine récepteur des oestrogènes |
US11642342B2 (en) * | 2019-12-23 | 2023-05-09 | Accutar Biotechnology | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA43141A (fr) * | 2016-07-12 | 2018-09-05 | Accutar Biotechnology Inc | Nouveaux composés et leurs utilisations |
US20220016102A1 (en) * | 2018-11-21 | 2022-01-20 | Shanghaitech University | Er protein regulators and use thereof |
WO2020106933A1 (fr) | 2018-11-21 | 2020-05-28 | Accutar Biotechnology Inc. | Nouveaux composés ayant une activité de dégradation des récepteur des oestrogènes alpha et leurs utilisations |
CN112390852B (zh) * | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
WO2021118629A1 (fr) * | 2019-12-12 | 2021-06-17 | Accutar Biotechnology Inc. | Nouveaux dérivés de chromane ayant une activité de dégradation des récepteurs des oestrogènes et leurs utilisations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207716B1 (en) * | 1994-04-25 | 2001-03-27 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
WO2014008159A1 (fr) * | 2012-07-03 | 2014-01-09 | The University Of North Carolina At Chapel Hill | Agents de dégradation sélectifs de récepteur des œstrogènes pour le traitement de tumeurs résistantes au tamoxifène |
US20140356322A1 (en) * | 2012-01-12 | 2014-12-04 | Yale University | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase |
US20160136230A1 (en) | 2013-07-03 | 2016-05-19 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5934986B2 (ja) * | 2011-09-07 | 2016-06-15 | 公益財団法人ヒューマンサイエンス振興財団 | アポトーシス阻害タンパク質リガンド−エストロゲン受容体リガンドハイブリッド化合物並びにそれを利用したエストロゲン受容体分解誘導剤及び乳癌、子宮頚癌又は卵巣癌の予防及び治療剤 |
US9896466B2 (en) * | 2013-04-24 | 2018-02-20 | Kkcg Ag | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level |
MA43141A (fr) * | 2016-07-12 | 2018-09-05 | Accutar Biotechnology Inc | Nouveaux composés et leurs utilisations |
-
2017
- 2017-07-11 MA MA043141A patent/MA43141A/fr unknown
- 2017-07-11 CN CN201780001677.9A patent/CN108495618B/zh not_active Expired - Fee Related
- 2017-07-11 WO PCT/US2017/041526 patent/WO2018013559A1/fr unknown
- 2017-07-11 CN CN201910655485.0A patent/CN110294788A/zh active Pending
- 2017-07-11 JP JP2019522609A patent/JP2019525955A/ja active Pending
- 2017-07-11 US US15/646,793 patent/US9944632B2/en active Active
- 2017-07-11 EP EP17828300.8A patent/EP3368011A4/fr not_active Withdrawn
- 2017-07-11 CA CA3030411A patent/CA3030411A1/fr not_active Abandoned
- 2017-07-11 AU AU2017297344A patent/AU2017297344A1/en not_active Abandoned
- 2017-07-11 KR KR1020197003884A patent/KR20190039125A/ko not_active Ceased
-
2018
- 2018-01-30 US US15/883,495 patent/US10450307B2/en not_active Expired - Fee Related
- 2018-12-21 HK HK18116445.7A patent/HK1257296A1/zh unknown
- 2018-12-24 HK HK18116500.9A patent/HK1257539A1/zh not_active IP Right Cessation
-
2019
- 2019-09-04 US US16/560,178 patent/US10968212B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207716B1 (en) * | 1994-04-25 | 2001-03-27 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US20140356322A1 (en) * | 2012-01-12 | 2014-12-04 | Yale University | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase |
WO2014008159A1 (fr) * | 2012-07-03 | 2014-01-09 | The University Of North Carolina At Chapel Hill | Agents de dégradation sélectifs de récepteur des œstrogènes pour le traitement de tumeurs résistantes au tamoxifène |
US20160136230A1 (en) | 2013-07-03 | 2016-05-19 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
Non-Patent Citations (10)
Title |
---|
BERNSTEIN, L. ET AL., J. NATL CANCER INST, vol. 91, 1999, pages 1654 - 62 |
CAREY ET AL.: "Advanced Organic Chemistry", 1990, PLENUM PRESS |
FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, vol. 50, no. 4, 1966, pages 219 - 244 |
GALDEANO ET AL., J. MED. CHEM., vol. 57, 2014, pages 8657 - 63 |
HIGUCHI ET AL.: "ACS Symposium Series", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "Prodrugs as Novel Delivery Systems" |
MORALES, A.R. ET AL., AM. J. CLIN. PATH., vol. 123, 2005, pages 21 - 27 |
MUNDY ET AL.: "Name Reaction and Reagents in Organic Synthesis", 2005, J. WILEY & SONS |
RING, A. ET AL., ENDOCR RELAT CANCER, vol. 11, 2004, pages 643 - 58 |
See also references of EP3368011A4 |
T.W. GREENEP.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020142227A1 (fr) * | 2019-01-03 | 2020-07-09 | The Regents Of The University Of Michigan | Agents de dégradation de protéine récepteur des oestrogènes |
US11642342B2 (en) * | 2019-12-23 | 2023-05-09 | Accutar Biotechnology | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
EP3368011A4 (fr) | 2019-07-10 |
US10968212B2 (en) | 2021-04-06 |
CN108495618A (zh) | 2018-09-04 |
CA3030411A1 (fr) | 2018-01-18 |
HK1257296A1 (zh) | 2019-10-18 |
US20180016269A1 (en) | 2018-01-18 |
US10450307B2 (en) | 2019-10-22 |
US20180208590A1 (en) | 2018-07-26 |
JP2019525955A (ja) | 2019-09-12 |
CN108495618B (zh) | 2019-08-16 |
KR20190039125A (ko) | 2019-04-10 |
AU2017297344A1 (en) | 2019-01-31 |
US20200024269A1 (en) | 2020-01-23 |
US9944632B2 (en) | 2018-04-17 |
EP3368011A1 (fr) | 2018-09-05 |
CN110294788A (zh) | 2019-10-01 |
HK1257539A1 (zh) | 2019-10-25 |
MA43141A (fr) | 2018-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10968212B2 (en) | Compounds having estrogen receptor alpha degradation activity and uses thereof | |
US10696659B2 (en) | Compounds having estrogen receptor alpha degradation activity and uses thereof | |
US11261178B2 (en) | Chroman derivatives having estrogen receptor degradation activity and uses thereof | |
US11535606B2 (en) | Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof | |
US20220220124A1 (en) | Novel compounds having bet, estrogen receptor, and androgen receptor degradation activity and uses thereof | |
EP2542254B1 (fr) | Agonistes du récepteur de nmda et leurs utilisations | |
US20230135173A1 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
US11220490B2 (en) | Ureas having androgen receptor degradation activity and uses thereof | |
KR20090024705A (ko) | 루테늄 ⅱ 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3030411 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019522609 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017297344 Country of ref document: AU Date of ref document: 20170711 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197003884 Country of ref document: KR Kind code of ref document: A |